Published in Int J Neuropsychopharmacol on February 19, 2009
A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder | NCT04210804
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A (2011) 2.37
Depression and risk of incident asthma in adults. The CARDIA study. Am J Respir Crit Care Med (2014) 1.53
Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology (2011) 1.44
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med (2016) 1.26
Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci (2009) 1.23
Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis (2009) 1.22
Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS One (2013) 1.18
Methamphetamine causes persistent immune dysregulation: a cross-species, translational report. Neurotox Res (2010) 1.09
Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis. J Neuroimmune Pharmacol (2012) 1.08
Salivary markers of inflammation in response to acute stress. Brain Behav Immun (2014) 1.06
Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci (2014) 1.01
Peripheral elevation of TNF-α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2013) 0.95
Neuroinflammation, neurodegeneration, and depression. Neurotox Res (2012) 0.95
In utero electroporation as a tool for genetic manipulation in vivo to study psychiatric disorders: from genes to circuits and behaviors. Neuroscientist (2011) 0.94
Body mass index and musculoskeletal pain: is there a connection? Chiropr Man Therap (2013) 0.93
Previous history of chronic stress changes the transcriptional response to glucocorticoid challenge in the dentate gyrus region of the male rat hippocampus. Endocrinology (2013) 0.90
The immunology of bipolar disorder. Neuroimmunomodulation (2014) 0.87
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol (2013) 0.87
Interleukin-1beta promoter (-31T/C and -511C/T) polymorphisms in major recurrent depression. J Mol Neurosci (2011) 0.82
Pathogenesis of depression: Insights from human and rodent studies. Neuroscience (2015) 0.82
Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review. Int J Mol Sci (2016) 0.81
Depression and altered serum lipids in cynomolgus monkeys consuming a Western diet. Physiol Behav (2011) 0.81
Imipramine reverses depressive-like parameters in pneumococcal meningitis survivor rats. J Neural Transm (Vienna) (2011) 0.81
Elevated levels of serum IL-5 are associated with an increased likelihood of major depressive disorder. BMC Psychiatry (2012) 0.80
Raised serum proinflammatory cytokines in Alzheimer's disease with depression. Aging Dis (2014) 0.79
Long-term functional recovery and compensation after cerebral ischemia in rats. Behav Brain Res (2014) 0.79
Orphanin FQ/nociceptin activates nuclear factor kappa B. J Neuroimmune Pharmacol (2011) 0.78
Molecular Neurobiology and Promising New Treatment in Depression. Int J Mol Sci (2016) 0.78
Increased expression of the anti-apoptotic protein Bcl-xL in the brain is associated with resilience to stress-induced depression-like behavior. Cell Mol Neurobiol (2012) 0.77
Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression? Am J Geriatr Psychiatry (2016) 0.77
Comorbidity Factors and Brain Mechanisms Linking Chronic Stress and Systemic Illness. Neural Plast (2016) 0.77
Dietary selenium deficiency exacerbates lipopolysaccharide-induced inflammatory response in mouse mastitis models. Inflammation (2014) 0.76
The role of orexin in post-stroke inflammation, cognitive decline, and depression. Mol Brain (2015) 0.76
Association analysis of the glucocorticoid receptor gene (NR3C1) haplotypes (ER22/23EK, N363S, BclI) with mood and anxiety disorders in patients with asthma. Exp Ther Med (2014) 0.76
The role of neuroimmune signaling in alcoholism. Neuropharmacology (2017) 0.76
Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness? World J Psychiatry (2016) 0.75
The impact of HIV/AIDS on compliance with antidepressant treatment in major depressive disorder: A prospective study in a South African private healthcare cohort. AIDS Res Ther (2015) 0.75
Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers. Sci Rep (2016) 0.75
The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence. Hum Brain Mapp (2016) 0.75
Deletion of the Fractalkine Receptor, CX3CR1, Improves Endogenous Repair, Axon Sprouting, and Synaptogenesis after Spinal Cord Injury in Mice. J Neurosci (2017) 0.75
The role of interleukin genes in the course of depression. Open Med (Wars) (2016) 0.75
Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus. J Neuroinflammation (2016) 0.75
Circuits Regulating Pleasure and Happiness-Mechanisms of Depression. Front Hum Neurosci (2016) 0.75
The role of the gut-brain axis in alcohol use disorders. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.75
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. Expert Rev Clin Pharmacol (2016) 0.75
N-acetylcysteine Prevents Alcohol Related Neuroinflammation in Rats. Neurochem Res (2017) 0.75
Strength and Aerobic Exercises Improve Spatial Memory in Aging Rats Through Stimulating Distinct Neuroplasticity Mechanisms. Mol Neurobiol (2016) 0.75
Dysfunction of Microglial STAT3 Alleviates Depressive Behavior via Neuron-Microglia Interactions. Neuropsychopharmacology (2017) 0.75
The Modulatory Role of Orexin 1 Receptor in CA1 on Orofacial Pain-induced Learning and Memory Deficits in Rats. Basic Clin Neurosci (2017) 0.75
A synaptic model of memory: long-term potentiation in the hippocampus. Nature (1993) 29.13
From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 15.90
The medial temporal lobe. Annu Rev Neurosci (2004) 11.98
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol (2005) 8.49
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
Synaptic scaling mediated by glial TNF-alpha. Nature (2006) 6.76
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet (2003) 4.84
Control of synaptic strength by glial TNFalpha. Science (2002) 4.46
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A (1998) 4.16
The stressed hippocampus, synaptic plasticity and lost memories. Nat Rev Neurosci (2002) 4.14
Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev (1998) 3.66
Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci (2005) 3.38
Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A (2003) 3.29
A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics (2003) 3.10
Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus (2006) 3.02
Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry (2005) 3.00
Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci (2001) 2.93
Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol (2002) 2.67
Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J Neurobiol (2004) 2.65
Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A (1989) 2.56
Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res (2004) 2.54
Depression: a case of neuronal life and death? Biol Psychiatry (2004) 2.45
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry (2006) 2.44
Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. Mol Psychiatry (2002) 2.43
Sickness behavior as a new target for drug development. Trends Pharmacol Sci (1992) 2.42
Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT (2003) 2.41
Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry (2007) 2.38
Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A (2005) 2.38
Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology (2000) 2.36
Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry (2001) 2.32
Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets (2007) 2.26
Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. Am J Psychiatry (2000) 2.25
Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry (2000) 2.21
Psychomotor stimulants and neuronal plasticity. Neuropharmacology (2004) 2.15
Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry (2008) 2.14
Case-control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. Br J Psychiatry (2002) 2.11
Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J Neurosci (2005) 2.02
Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry (2000) 1.97
Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry (2004) 1.95
Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol (2005) 1.94
Acute cortisone administration impairs retrieval of long-term declarative memory in humans. Nat Neurosci (2000) 1.90
Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Arch Gen Psychiatry (1999) 1.89
Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol (1990) 1.89
Clinical depression and regulation of the inflammatory response during acute stress. Psychosom Med (2005) 1.83
Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse (2000) 1.82
"Inflammatory" cytokines: neuromodulators in normal brain? J Neurochem (2000) 1.80
Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci (1998) 1.80
A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology (2007) 1.77
Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci (2002) 1.77
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Stress and plasticity in the limbic system. Neurochem Res (2003) 1.73
3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry (2000) 1.72
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Synthesis of interleukin 1/endogenous pyrogen in the brain of endotoxin-treated mice: a step in fever induction? J Immunol (1984) 1.71
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci Lett (1996) 1.70
TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry (2006) 1.67
Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol (2002) 1.67
A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry (2008) 1.66
Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology (2005) 1.65
Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord (1995) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun (2003) 1.60
The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol (2002) 1.60
Memory for context is impaired by a post context exposure injection of interleukin-1 beta into dorsal hippocampus. Behav Brain Res (2002) 1.58
Interleukin 1 beta inhibits synaptic strength and long-term potentiation in the rat CA1 hippocampus. Brain Res (1993) 1.54
On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry Neuropsychol Behav Neurol (1998) 1.53
Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus (2003) 1.52
p53: 25 years after its discovery. Trends Pharmacol Sci (2004) 1.49
Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull (2001) 1.49
Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS Neurol Disord Drug Targets (2007) 1.47
A neuromodulatory role of interleukin-1beta in the hippocampus. Proc Natl Acad Sci U S A (1998) 1.47
Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci U S A (1997) 1.46
Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) (2003) 1.46
Interleukin-6: a cytokine to forget. FASEB J (2004) 1.45
Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci (2004) 1.45
Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci (1998) 1.44
Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res (2003) 1.42
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41
How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med (2000) 1.41
Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.40
Anti-inflammatory properties of desipramine and fluoxetine. Respir Res (2007) 1.38
Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett (1992) 1.38
Low levels of circulating inflammatory cytokines--do they affect human brain functions? Brain Behav Immun (2002) 1.38
Cytokine actions in the central nervous system. Cytokine Growth Factor Rev (1999) 1.38
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology (2001) 1.37
Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.37
Anterograde amnesia and temporally graded retrograde amnesia for a nonspatial memory task after lesions of hippocampus and subiculum. J Neurosci (2002) 1.37
Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci (1999) 1.34
Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol (2007) 1.34
The long-term potential of LTP. Nat Rev Neurosci (2003) 1.33
Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr (2008) 1.33
Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res (1999) 1.32
Cell pathology in mood disorders. Semin Clin Neuropsychiatry (2002) 1.30
Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord (2002) 1.30
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry (2004) 1.29
Behavioral effects of cytokines. Brain Behav Immun (2001) 1.29
Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A (2002) 13.58
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Unbiased whole-genome amplification directly from clinical samples. Genome Res (2003) 6.29
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Just what the doctor ordered. Review of the evidence of the impact of computerized physician order entry system on medication errors. Health Serv Res (2008) 2.05
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology (2010) 1.96
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol (2012) 1.73
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Genome-wide association analyses in Han Chinese identify two new susceptibility loci for amyotrophic lateral sclerosis. Nat Genet (2013) 1.57
The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53
Obesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. Diabetes (2008) 1.52
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
In vitro fabrication of a tissue engineered human cardiovascular patch for future use in cardiovascular surgery. Ann Thorac Surg (2006) 1.47
Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci (2004) 1.45
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology (2007) 1.42
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41
Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology (2008) 1.41
In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 1.41
Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med (2010) 1.41
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40
Molecular effects of lithium. Mol Interv (2004) 1.39
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest (2014) 1.38
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry (2009) 1.33
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry (2004) 1.29
The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry (2009) 1.29
Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2008) 1.29
Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics (2008) 1.26
Endophenotypes in bipolar disorder. Am J Med Genet (2002) 1.25
BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A (2008) 1.25
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology (2006) 1.24
Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24
Thermochromic VO2 thin films: solution-based processing, improved optical properties, and lowered phase transformation temperature. Langmuir (2010) 1.23
Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics (2010) 1.23
Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry (2006) 1.23
Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets (2006) 1.23
Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response. Neuroreport (2009) 1.23
Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep (2006) 1.22
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
Differential DNA methylation in discrete developmental stages of the parasitic nematode Trichinella spiralis. Genome Biol (2012) 1.16
Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol (2006) 1.16
Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage (2009) 1.16
Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology (2007) 1.16
Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol (2005) 1.15
Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry (2006) 1.13
High accuracy genotyping directly from genomic DNA using a rolling circle amplification based assay. BMC Genomics (2003) 1.13
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology (2003) 1.13
Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry (2006) 1.13
Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry (2006) 1.12
G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta (2006) 1.12
Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci (2003) 1.11
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J (2005) 1.11
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol (2012) 1.11
Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. Behav Brain Res (2008) 1.10
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci (2005) 1.10
In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry (2007) 1.10
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09